Larotrectinib has been launched in China and is suitable for NTRK gene fusion positive solid tumor patients. The product name is "Vitrakvi" and...
Larotrectinib, as a broad-spectrum anti-cancer targeted drug with NTRK gene fusion positivity, has been clinically studied to have significant ...
Larotrectinib has been launched in China and is suitable for solid tumor patients with NTRK gene fusion positivity. When using it, attention sh...
Larotrectinib should be taken as a whole tablet, and the recommended dosage should be adjusted according to age and weight. It can be taken wit...
Esbriet is recommended to be taken with meals to reduce the risk of gastrointestinal adverse reactions. It should be administered three times a...
Ongentys is a COMT inhibitor used for the treatment of Parkinson's disease, and special attention should be paid to drug interactions, neurolog...
Ongentys, as a third-generation COMT inhibitor, improves motor fluctuations in Parkinson's disease by prolonging the action time of levodopa. H...
Ongentys (Opicapone), as a third-generation COMT inhibitor, is mainly used as an adjuvant therapy for Parkinson's disease patients, improving m...
As a COMT inhibitor, the side effects of Ongentys involve multiple system reactions such as cardiovascular and nervous system reactions, and sp...
At present, there is no generic drug of Eplerenone on the market in China. The original product name of the drug is Inspra, developed by Pfizer...